Pankreal (Pancreatin)

Pancreatin, the active ingredient in Pankreal, is a digestive enzyme presented as a pancreatic enzyme replacement therapy for oral use. It aids digestion in patients with pancreatic insufficiency, including those with cystic fibrosis, chronic pancreatitis, and post‑surgical states. GNH USA supplies Pankreal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

GNH USA supplies Pankreal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Pankreal is a pancreatic enzyme preparation that acts on the digestive tract to improve nutrient breakdown.

- Cystic fibrosis: enhances digestion of fats, proteins and carbohydrates, reducing steatorrhea. - Chronic pancreatitis: supplements deficient pancreatic enzymes, improving nutrient absorption. - Post‑pancreatectomy: provides exogenous enzymes to support digestion after surgical removal of pancreatic tissue. - Pancreatic exocrine insufficiency (PEI): restores enzymatic activity for better digestion and nutritional status.

Adverse reactions to pancreatic enzyme products are generally mild and related to the gastrointestinal tract.

Common Side Effects: - Abdominal discomfort: mild cramping or bloating. - Flatulence: increased intestinal gas. - Nausea: occasional feeling of queasiness. - Diarrhoea: loose stools. - Constipation: reduced bowel movements. - Skin rash: mild erythema at the application site.

Serious or Rare Side Effects: - Fibrosing colonopathy: rare narrowing of the colon associated with high‑dose therapy. - Severe allergic reaction: anaphylaxis, angioedema or urticaria. - Pancreatitis: inflammation of the pancreas. - Persistent vomiting: ongoing emesis despite dose adjustment. - Intestinal obstruction: blockage due to bezoar formation. - Hyperuricaemia: elevated uric acid levels in susceptible individuals.

When using Pankreal, consider the following safety measures:

- Dose adjustment: tailor the dose to the individual’s dietary fat content and clinical response. - Monitoring: regularly assess nutritional status, weight and stool fat content. - Allergic history: avoid use in patients with known hypersensitivity to porcine‑derived products. - Concomitant acid‑suppressive therapy: may reduce enzyme activation; dose may need modification. - Pregnancy and lactation: limited data; use only if clearly needed. - Store at ambient temperature: keep in the original packaging   ---    ​     ---  --- ---  ---  --- ---

Store  ​   --- ​  “  "   "  "  "  " " " " " " " "" 

Pankreal  ​           ​   “  “   “